Document Detail


In vivo demonstration of an antithrombin effect of abciximab.
MedLine Citation:
PMID:  10913474     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Abciximab prolonged the activated clotting time (ACT) in a post hoc analysis from the Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications trial and an in vitro study has suggested an antithrombin effect of platelet glycoprotein IIb/IIIa inhibition. The purpose of this study was to evaluate the in vivo effects of abciximab on ACT and thrombin generation. In 46 patients undergoing coronary intervention, 24 received heparin and abciximab (group I), whereas 22 received heparin alone (group II). All received the same dose (70 U/kg) of heparin. Heparin was given after a baseline ACT, and in group I, abciximab was administered after the 5-minute ACT. Serial ACTs were recorded at baseline, 5, 10, 20, and every 30 minutes thereafter and at the procedure's end. No intervention including balloon angioplasty was performed until after the 20-minute ACT. The prothrombin fragment F1.2 (Nm/L) was measured at baseline, 20 minutes, and at the end of the procedure. Before (baseline) heparin and at 5 minutes, ACTs were similar. Abciximab prolonged ACT by a mean of 34 to 64 seconds starting with the 10-minute ACT and extending to the 50-minute ACT (all p <0.01 vs heparin alone). There was a progressive decrease in the F1.2 with abciximab, and baseline minus end F1.2 was 0.12 +/- 0.02 in group I versus 0.05 +/- 0.04 in group II, p <0.05. These data indicate a significant in vivo effect of abciximab plus heparin in increasing ACT and decreasing F1.2, results that are consistent with an effect on reducing thrombin generation.
Authors:
J A Ambrose; M Hawkey; J J Badimon; J Coppola; J Geagea; K P Rentrop; A Domiguez; S Duvvuri; T Elmquist; J Arias; R Doss; G Dangas
Related Documents :
11011804 - Comparative pharmacokinetics of lmwhs.
18041724 - Hemocompatible albumin-heparin coatings prepared by the layer-by-layer technique. the e...
6883814 - In vivo complement activation by polyanion--polycation complexes: evidence that c5a is ...
16404704 - Effect of hirudin versus heparin on hemocompatibility of blood contacting biomaterials:...
6580854 - Labelled-calcium release from rat mandibles exposed to prostaglandins in vitro.
6890244 - Prostaglandin synthesis in aorta and platelets of fawn-hooded rats with platelet storag...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  The American journal of cardiology     Volume:  86     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2000 Jul 
Date Detail:
Created Date:  2000-08-17     Completed Date:  2000-08-17     Revised Date:  2013-05-24    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  150-2     Citation Subset:  AIM; IM    
Affiliation:
Comprehensive Cardiovascular Center, Saint Vincents Hospital and Medical Center, 170 West 12th Street, New York, New York 10011, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal / pharmacology*
Anticoagulants / pharmacology*
Antithrombins / pharmacology*
Clinical Trials as Topic
Coronary Disease / blood
Female
Heparin / pharmacology
Humans
Immunoglobulin Fab Fragments / pharmacology*
Male
Middle Aged
Prothrombin / analysis
Whole Blood Coagulation Time
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Anticoagulants; 0/Antithrombins; 0/Immunoglobulin Fab Fragments; 9001-26-7/Prothrombin; 9005-49-6/Heparin; X85G7936GV/abciximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A prospective study of dominance and coronary heart disease in the Normative Aging Study.
Next Document:  Comparison of baseline and low-dose dobutamine technetium-99m sestamibi scintigraphy with low-dose d...